Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities.
Clin Exp Rheumatol
; 31(4 Suppl 78): S28-32, 2013.
Article
in En
| MEDLINE
| ID: mdl-24129133
ABSTRACT
Many studies have been conducted concerning discontinuation of biologic disease-modifying anti-rheumatic drugs (DMARD), but mainly in trial settings which result in limited generalisability. Registry studies can complement the current literature of biologic DMARD discontinuation by providing more generalisable information. However, it may be necessary to combine registries to increase power and provide more diverse patient populations. This increased power could provide us information about risk and benefits of discontinuing biologic DMARD in typical clinical practice. However, use of multiple registries is not without challenges. In this review, we discuss the challenges to combining data across multiple registries, focusing on biologic discontinuation as an example. Challenges include 1) generalizability of each registry; 2) new versus prevalent users designs; 3) outcome definitions; 4) different health care systems; 5) different follow up intervals; and 6) data harmonisation. The first three apply to each registry, and the last three apply to combining multiple registries. This review describes these challenges, corresponding solutions, and potential future opportunities.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Arthritis, Rheumatoid
/
Biological Products
/
Registries
/
Antirheumatic Agents
/
Data Mining
Type of study:
Diagnostic_studies
Limits:
Humans
Language:
En
Journal:
Clin Exp Rheumatol
Year:
2013
Document type:
Article
Affiliation country:
United States